Ore Pharmaceuticals Inc. (NASDAQ: ORXE) announced today that it has initiated dosing subjects with GL1001, the Company's lead drug candidate, in a multiple ascending dose clinical trial.

Ore Pharmaceuticals Inc. (NASDAQ:ORXE) announced today that it has acquired from Roche the exclusive development rights for the clinical-stage compound romazarit.

Ore Pharmaceuticals Inc. (NASDAQ:ORXE) announced today that it has acquired from Roche the clinical-stage compound tiapamil.

Ore Pharmaceuticals Inc. (NASDAQ:ORXE) announced today that it has filed an investigational new drug (IND) application with the U.S. Food and Drug Administration (FDA) for GL1001, the first clinical-stage inhibitor of the ACE2 enzyme.

Ore Pharmaceuticals Inc. (NASDAQ:ORXED) announced today that DioGenix, its molecular diagnostics subsidiary, has identified novel sets of genes that it believes will form the basis of a new assay to diagnose multiple sclerosis (MS), a disease of the central nervous system (CNS).